The two pharma companies – both active in trying to develop new therapies for the neurodegenerative disorder – are starting a two-year trial of Roche Diagnostics’ Elecsys Amyloid Plasma ...

Results from 604 participants in a multicenter study of Roche’s (RHHBY) Elecsys pTau181 plasma test were presented, demonstrating its potential to accurately rule out amyloid pathology ...

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle™ AD study Data on the Elecsys ... s disease Roche will initiate ...

Results from 604 participants in a multicenter study of Roche’s Elecsys pTau181 plasma test were presented, demonstrating its potential to accurately rule out amyloid pathology, a hallmark of ...